Essential hypertension in the pathogenesis of age-related macular degeneration: a review of the current evidence.

Age-related macular degeneration (AMD) is one of the main causes of vision loss, especially in the elderly. The involvement of essential hypertension in its pathogenesis has been well covered in the literature since it was first recognized. Hemodynamic abnormalities appear to contribute to AMD, with the renin-angiotensin system playing a significant role. Many studies have demonstrated that high blood pressure is associated with lower choroidal blood flow and disturbed vascular homeostasis in these patients. In addition, AMD is characterized by abnormal neovascularization, to which angiotensin II and growth factors make a large contribution. Most epidemiological studies have found essential hypertension to be a risk factor for AMD. However, although all agree that the strongest predisposing factors are age and smoking, overall there is some inconsistency regarding the exact role of hypertension in its pathogenesis. In particular, there are no data in the literature to support the view that antihypertensive medication and the successful management of hypertension have a positive effect on the clinical outcome of AMD. This reinforces the data indicating that the cause of AMD is multifactorial and suggests that, although essential hypertension probably plays a role, in itself it is unlikely to be a major contributor to the future occurrence of AMD.

[1]  S. Song,et al.  Age-Related Macular Degeneration Prevalence and Risk Factors from Korean National Health and Nutrition Examination Survey , 2008 through 2011 , 2014 .

[2]  P. Mitchell,et al.  Prevalence, racial variations, and risk factors of age-related macular degeneration in Singaporean Chinese, Indians, and Malays. , 2014, Ophthalmology.

[3]  T. Wong,et al.  ASSOCIATIONS BETWEEN CARDIOVASCULAR RISK FACTORS AND EARLY AGE-RELATED MACULAR DEGENERATION IN A RURAL CHINESE ADULT POPULATION , 2014, Retina.

[4]  Chelsea E. Myers,et al.  Vasodilators, blood pressure-lowering medications, and age-related macular degeneration: the Beaver Dam Eye Study. , 2014, Ophthalmology.

[5]  P. Barberger‐Gateau,et al.  Elevated High-Density Lipoprotein Cholesterol and Age-Related Macular Degeneration: The Alienor Study , 2014, PloS one.

[6]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[7]  A. Sjølie,et al.  Cardiovascular risk factors associated with age‐related macular degeneration: the Tromsø Study , 2014, Acta ophthalmologica.

[8]  B. Yaspan,et al.  Mechanisms of age‐related macular degeneration and therapeutic opportunities , 2014, The Journal of pathology.

[9]  P. Barberger‐Gateau,et al.  Long-term blood pressure and age-related macular degeneration: the ALIENOR study. , 2013, Investigative ophthalmology & visual science.

[10]  Roberta McKean-Cowdin,et al.  Risk factors for four-year incidence and progression of age-related macular degeneration: the los angeles latino eye study. , 2011, American journal of ophthalmology.

[11]  G. Striker,et al.  Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. , 2011, The American journal of pathology.

[12]  P. Mitchell,et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis , 2010, BMC ophthalmology.

[13]  Merlin C. Thomas,et al.  Candesartan Attenuates Diabetic Retinal Vascular Pathology by Restoring Glyoxalase-I Function , 2010, Diabetes.

[14]  G. Ying,et al.  Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation. , 2010, American journal of ophthalmology.

[15]  G. Remuzzi,et al.  Angiotensin II revisited: new roles in inflammation, immunology and aging , 2010, EMBO molecular medicine.

[16]  R. Klein,et al.  Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. , 2008, American journal of ophthalmology.

[17]  P. Mitchell,et al.  Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. , 2007, Ophthalmology.

[18]  H. Okano,et al.  Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. , 2006, Investigative ophthalmology & visual science.

[19]  G. Lip,et al.  Oxidative stress and hypertension , 2006, International journal of clinical practice.

[20]  P. Edwards,et al.  Role of angiotensin II in retinal leukostasis in the diabetic rat. , 2006, Experimental eye research.

[21]  K. Tsubota,et al.  Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  G. Ying,et al.  Effect of systemic hypertension on foveolar choroidal blood flow in age related macular degeneration , 2006, British Journal of Ophthalmology.

[23]  C. Curcio,et al.  Basal deposits and drusen in eyes with age-related maculopathy: evidence for solid lipid particles. , 2005, Experimental eye research.

[24]  P. Campochiaro Ocular neovascularisation and excessive vascular permeability , 2004, Expert opinion on biological therapy.

[25]  B. Munoz,et al.  Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. , 2004, Archives of ophthalmology.

[26]  P. Mitchell,et al.  Angiotensin-converting enzyme inhibitors (ACEIs) and age-related maculopathy (ARM): cross-sectional findings from the Blue Mountains Eye Study. , 2004, Acta ophthalmologica Scandinavica.

[27]  J. Ambati,et al.  Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[28]  K. Csaky,et al.  Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[29]  T. Hisatomi,et al.  The critical role of ocular‐infiltrating macrophages in the development of choroidal neovascularization , 2003, Journal of leukocyte biology.

[30]  R. Klein,et al.  Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. , 2003, Ophthalmology.

[31]  Ronald Klein,et al.  The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. , 2003, Ophthalmology.

[32]  J. Jonas,et al.  Influence of arterial hypertension and diet-induced atherosclerosis on macular drusen , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  T. Hikichi,et al.  Inhibitory effect of losartan on laser-induced choroidal neovascularization in rats. , 2001, American journal of ophthalmology.

[34]  H. Takagi,et al.  Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. , 2001, Diabetes.

[35]  M. Cooper,et al.  Retinal Neovascularization Is Prevented by Blockade of the Renin-Angiotensin System , 2000, Hypertension.

[36]  M. C. Leske,et al.  Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. , 2000, Archives of ophthalmology.

[37]  P. Kulkarni,et al.  Angiotensin II-induced constrictions are masked by bovine retinal vessels. , 1999, Investigative ophthalmology & visual science.

[38]  K. Suzuma,et al.  Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. , 1998, Circulation research.

[39]  R. Klein,et al.  The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: the Beaver Dam Eye Study. , 1997, Ophthalmology.

[40]  D. R. Anderson,et al.  Suppression of CO2-induced relaxation of bovine retinal pericytes by angiotensin II. , 1997, Investigative ophthalmology & visual science.

[41]  D. Alcorn,et al.  Renin-containing Müller cells of the retina display endocrine features. , 1995, Investigative ophthalmology & visual science.

[42]  P T de Jong,et al.  An international classification and grading system for age-related maculopathy and age-related macular degeneration , 1995 .

[43]  W R Green,et al.  Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.

[44]  R. Klein,et al.  The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. , 1993, Ophthalmology.

[45]  M. Zarbin,et al.  Ocular penetration of thiabendazole. , 1990, Archives of ophthalmology.

[46]  N. Bressler,et al.  Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. , 1990, Archives of ophthalmology.

[47]  R. Sperduto,et al.  Systemic hypertension and age-related maculopathy in the Framingham Study. , 1986, Archives of ophthalmology.

[48]  A. Chetrit,et al.  Time trends in the incidence and causes of blindness in Israel. , 2013, American journal of ophthalmology.

[49]  G. Ying,et al.  Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[50]  Usha Chakravarthy,et al.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.

[51]  Michael I Dorrell,et al.  Ocular neovascularization: basic mechanisms and therapeutic advances. , 2007, Survey of ophthalmology.

[52]  S. Yamagishi,et al.  Pericyte biology and diseases. , 2005, International journal of tissue reactions.

[53]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[54]  A. Hofman,et al.  Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. , 2003, Investigative ophthalmology & visual science.

[55]  A Hofman,et al.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study. , 2001, Investigative ophthalmology & visual science.

[56]  C. Curcio,et al.  Accumulation of cholesterol with age in human Bruch's membrane. , 2001, Investigative ophthalmology & visual science.

[57]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[58]  J. Guyton,et al.  Development of the lipid-rich core in human atherosclerosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[59]  Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. , 1994, Archives of ophthalmology.